IN BRIEF: RTW Venture Fund takes part in Kyverna funding round

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical ...

Alliance News 26 January, 2022 | 7:14PM
Email Form Facebook Twitter LinkedIn RSS

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Takes part in Series B financing round worth USD85 million into Kyverna Therapeutics Inc.

Kyverna is a cell therapy firm which is developing a new class of therapies for autoimmune and inflammatory disease.

Proceeds from the funding round will go towards the initiation of a phase two clinical trial for the company's lead asset KYV-101, scheduled for the first half of 2022.

Current stock price: USD1.50

12-month change: down 32%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
RTW Venture Ord 1.17 USD -0.43 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.